CTOs on the Move

Beth Israel Deaconess Hospital-Needham

www.bidneedham.org

 
BID Needham, part of Beth Israel Lahey Health, is focused on providing our patients with easy access to compassionate, safe and high-quality health care.
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details

Similar Companies

MAP Pharmaceuticals

MAP Pharmaceuticals is a Mountain View, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cardurion

Cardurion Pharmaceuticals is a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the treatment of cardiovascular diseases. Founded by physician-scientist, Michael E. Mendelsohn, M.D., and built by a team of physician-scientists and industry leaders with extensive experience in cardiovascular disease, drug development and business development, Cardurion Pharmaceuticals is pursuing unique drug discovery and development programs to target major unmet needs in cardiovascular medicine. Cardurion Pharmaceuticals has facilities in Burlington, Massachusetts and Shonan, Japan.

Miller Pharmacy

Miller Pharmacy is a Kansas City, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BELLWYCK PACKAGING SOLUTIONS

BELLWYCK PACKAGING SOLUTIONS is a Owen Sound, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pharvaris

Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE. The company reunites the core team responsible for the discovery and approval of the HAE treatment icatibant. With novel small molecules, we have identified and are advancing potent, orally available compounds targeting this clinically proven therapeutic target.